Impact of lifetime lactation on the risk and duration of frequent vasomotor symptoms: A longitudinal dose-response analysis
- PMID: 35993429
- PMCID: PMC9729369
- DOI: 10.1111/1471-0528.17274
Impact of lifetime lactation on the risk and duration of frequent vasomotor symptoms: A longitudinal dose-response analysis
Abstract
Objective: To examine the association between lifetime lactation and risk and duration of frequent vasomotor symptoms (VMS).
Design: Prospective cohort.
Setting: USA, 1995-2008.
Sample: 2356 parous midlife women in the Study of Women's Health Across the Nation.
Methods: Lifetime lactation was defined as the duration of breastfeeding across all births in months. We used generalised estimating equations to analyse risk of frequent VMS and Cox regression to analyse duration of frequent VMS in years.
Main outcome measures: Frequent VMS (hot flashes and night sweats) were measured annually for 10 years, defined as occurring ≥6 days in the past 2 weeks.
Results: Overall, 57.1% of women reported hot flashes and 43.0% reported night sweats during follow-up. Lifetime lactation was inversely associated with hot flashes plateauing at 12 months of breastfeeding (6 months: adjusted odds ratio [AOR] 0.85, 95% confidence interval (CI) 0.75-0.96; 12 months: AOR 0.78, 95% CI 0.65-0.93) and was inversely associated with night sweats in a downward linear fashion (6 months: AOR 0.93, 95% CI 0.81-1.08; 18 months: AOR 0.82, 95% CI 0.67-1.02; 30 months: AOR 0.73, 95% CI 0.56-0.97). Lifetime lactation was associated with shorter duration of hot flashes and night sweats in a quadratic (bell-shaped) fashion. The association was strongest at 12-18 months of breastfeeding and significant for hot flashes (6 months: adjusted hazard ratio [AHR] 1.35, 95% CI 1.11-1.65; 18 months: AHR 1.54, 95% CI 1.16-2.03; 30 months: AHR 1.18, 95% CI 0.83-1.68).
Conclusions: Longer lifetime lactation is associated with decreased risk and duration of frequent VMS.
Keywords: breastfeeding; hot flashes; menopause; middle-aged; prospective studies; sweating; women's health.
© 2022 John Wiley & Sons Ltd.
Conflict of interest statement
DISCLOSURES OF INTEREST
AKS has received honoraria from Pfizer and Bio-Syent, and has received grant funding from Pfizer. PDF is a shareholder and consultant and receives payment in convertible notes from ViTAA medical devices. EAB has received speaking fees from Searchlight Pharmaceuticals. NVS has no disclosures to report.
Figures




References
-
- Deecher DC, Dorries K. Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Arch Womens Ment Health. 2007;10(6):247–57. - PubMed
-
- Williams RE, Kalilani L, DiBenedetti DB, Zhou X, Granger AL, Fehnel SE, et al. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric. 2008;11(1):32–43. - PubMed
-
- Williams RE, Kalilani L, DiBenedetti DB, Zhou X, Fehnel SE, Clark RV. Healthcare seeking and treatment for menopausal symptoms in the United States. Maturitas. 2007;58(4):348–58. - PubMed
MeSH terms
Grants and funding
- U01NR004061/NH/NIH HHS/United States
- U01AG012539/NH/NIH HHS/United States
- U01AG012505/NH/NIH HHS/United States
- R01 AG062622/AG/NIA NIH HHS/United States
- U01AG012535/NH/NIH HHS/United States
- U01AG012495/NH/NIH HHS/United States
- CIHR/Canada
- U01 AG012505/AG/NIA NIH HHS/United States
- U01 AG012531/AG/NIA NIH HHS/United States
- U01 AG012554/AG/NIA NIH HHS/United States
- U01AG012546/NH/NIH HHS/United States
- U01AG012531/NH/NIH HHS/United States
- U01 AG012535/AG/NIA NIH HHS/United States
- U01 AG012553/AG/NIA NIH HHS/United States
- U01 NR004061/NR/NINR NIH HHS/United States
- U01AG012554/NH/NIH HHS/United States
- U01 AG012539/AG/NIA NIH HHS/United States
- U01 AG012546/AG/NIA NIH HHS/United States
- U01AG012553/NH/NIH HHS/United States
- U01 AG012495/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Miscellaneous